Randomized Phase II Designs

Haitao Pan () and Ying Yuan ()
Additional contact information
Haitao Pan: St. Jude Children’s Research Hospital, Department of Biostatistics
Ying Yuan: The University of Texas MD Anderson Cancer Center, Department of Biostatistics

Chapter Chapter 7 in Bayesian Adaptive Design for Immunotherapy and Targeted Therapy, 2023, pp 119-146 from Springer

Abstract: Abstract Compared to single-arm phase II trials, randomized phase II trials provide a more reliable way to assess the efficacy of experimental drugs and make the Go/No-Go decision. This chapter introduces a frequentist design, followed by several Bayesian randomized phase II designs, including randomized Bayesian optimal phase 2 (BOP2) design and two-stage screened selection design. This chapter focuses on Bayesian designs because of their flexibility and efficiency to handle the complexity of immunotherapies and targeted therapies that may involve binary, survival, ordinal, co-primary and multiple endpoints. A two-stage screened selection design (SSD) for randomized trials but without the control treatment is also introduced. Software to implement these designs are described.

Date: 2023
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-981-19-8176-0_7

Ordering information: This item can be ordered from
http://www.springer.com/9789811981760

DOI: 10.1007/978-981-19-8176-0_7

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().